---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-097885"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2025-07-23T23:59:59+00:00"
generated_at: "2026-05-18T03:28:18.479854+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Viking Therapeutics Q2 net loss $65.6M; Phase 3 VANQUISH obesity trial underway

## Summary
- Net loss $65.6M ($0.58/share) vs $22.3M ($0.20) in Q2 2024; R&D spend $60.2M vs $23.8M.
- Cash and investments $808M as of June 30, 2025, down from $903M at Dec 31, 2024.
- Phase 3 VANQUISH program initiated: two placebo-controlled trials (obesity and obesity+type 2 diabetes) targeting ~5,600 patients.
- Phase 2 VENTURE-Oral dosing trial enrollment completed (~280 patients); top-line results expected 2H25.
- Amylin agonist program progressing; IND filing planned for Q4 2025.

## SEC filing metadata
- accession: 0000950170-25-097885
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2025-07-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000095017025097885/0000950170-25-097885-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000095017025097885/vktx-20250723.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-097885
- JSON: https://secwatch.observer/filing/0000950170-25-097885.json
- Plain text: https://secwatch.observer/filing/0000950170-25-097885.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.